

Estimated Vaccination Coverage^{†} among Adolescents Aged 13-17 Years[§], by Race/Ethnicity[¶] for Selected Vaccines -- National Immunization Survey-Teen, United States, 2014**

Vaccines	White only, non-Hispanic	Black only, non-Hispanic	Hispanic	American Indian/Alaska Native only, non-Hispanic	Asian, non-Hispanic
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Td or Tdap					
≥1 dose Td or Tdap ^{**}	90.3(±0.8)	89.6(±2.0)	90.4(±2.0)	88.2(±6.1)	87.7(±6.6)
≥1 dose Tdap ^{††}	88.6(±0.9)	87.6(±2.1)	86.7(±2.4)	86.1(±6.5)	85.2(±6.7)
≥1 dose MenACWY ^{§§}	78.2(±1.2)	80.3(±2.8)	82.1(±2.8)	73.5(±9.2)	82.5(±6.5)
HPV^{¶¶}					
FEMALE					
≥1 dose	56.1(±2.2)	66.4(±4.8)	66.3(±5.1)	71.2(±14.4)	54.9(±9.3)
≥2 doses	47.1(±2.2)	53.0(±5.1)	57.4(±5.1)	61.8(±15.6)	47.5(±9.1)
≥3 doses	37.5(±2.1)	39.0(±5.0)	46.9(±5.2)	39.4(±15.4)	35.7(±8.2)
MALE					
≥1 dose	36.4(±2.0)	42.1(±4.9)	54.2(±4.9)	49.8(±13.9)	45.8(±11.4)
≥2 doses	27.4(±1.9)	32.0(±4.8)	39.4(±4.9)	40.5(±13.1)	38.3(±11.1)
≥3 doses	18.8(±1.7)	20.4(±4.0)	27.8(±4.7)	26.3(±10.9)	26.6(±10.4)
HPV 3 dose series completion^{***}					
Females	70.6(±3.2)	61.6(±6.3)	72.8(±5.4)	55.4(±22.5)	71.7(±11.0)
Males	57.9(±3.6)	54.1(±8.1)	57.2(±7.0)	57.7(±17.5)	63.0(±17.0)
≥2 doses MMR ^{†††}	91.0(±0.9)	91.1(±1.9)	90.5(±1.9)	94.1(±4.1)	85.8(±6.9)
≥ 3 doses Hepatitis B ^{§§§}	92.2(±0.8)	91.4(±1.8)	90.5(±1.9)	93.9(±4.3)	85.5(±6.9)
Varicella					
History of varicella disease ^{¶¶¶}	20.2(±1.2)	18.3(±2.8)	23.3(±3.1)	36.1(±11.8)	23.2(±7.3)
Among adolescents without a history of varicella disease:					
≥1 dose	95.1(±0.7)	95.3(±1.4)	95.5(±1.5)	96.1(±3.4)	92.4(±4.2)
≥2 doses	80.0(±1.4)	84.6(±2.5)	82.5(±3.1)	84.7(±6.7)	82.3(±5.5)
History of disease or received ≥2 doses varicella vaccine	84.0(±1.1)	87.4(±2.1)	86.6(±2.4)	90.2(±4.5)	86.4(±4.4)

Abbreviations: Td = tetanus toxoid, reduced diphtheria toxoid; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis; MenACWY = meningococcal conjugate; HPV = human papilloma virus; MMR = measles, mumps, and rubella; CI = confidence interval

* Estimate presented as point estimate (%) ± 95% CI.

† Estimates with CI >20 may not be reliable.

§ Adolescents in the 2014 NIS-Teen were born January 1996 through February 2002. Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. National estimates do not include adolescents living in Puerto Rico (n=230).

¶ Reported by parent/guardian respondent. Adolescents of Hispanic ethnicity may be of any race. Native Hawaiian or other Pacific Islanders and persons of multiple races were not included because of small sample sizes.

** ≥1 dose of Td or Tdap vaccine since age 10 years.

†† ≥1 dose of Tdap vaccine since age 10 years.

§§ ≥1 dose of MenACWY or meningococcal -unknown type vaccine.

¶¶ HPV vaccine, either quadrivalent or bivalent. Percentages reported among females (n = 10,084) and males (n = 10,743). Some adolescents might have received more than the 3 recommended HPV vaccine doses.

*** Percent of adolescents who received ≥ 3 HPV vaccine doses among those who had ≥ 1 HPV vaccine dose with at least 24 weeks between the first dose and the interview date. The denominator for this calculation was limited to females (n = 5,703) and males (n = 3,935) who received their first HPV dose and had enough time to receive the third HPV dose.

††† ≥ 2 doses of MMR vaccine.

§§§ ≥3 doses of hepatitis B vaccine.

¶¶¶ By parent/guardian report or provider records.